1
|
Selmi B, Deval J, Boretto J, Canard B. Nucleotide Analogue Binding, Catalysis and Primer Unblocking in the Mechanisms of HIV-1 Reverse Transcriptase-Mediated Resistance to Nucleoside Analogues. Antivir Ther 2003. [DOI: 10.1177/135965350300800209] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Nucleoside analogues play a key role in the fight against HIV-1. Unfortunately, under therapeutic pressure, HIV-1 inevitably develops resistance to these inhibitors. This resistance correlates with specific pol gene mutations giving rise to specific substitutions in reverse transcriptase that are responsible for the loss of efficacy of the corresponding analogue. This work is an overview of the molecular mechanisms of HIV-1 drug resistance as judged by the analysis of chemical reactions at play at the reverse transcriptase active site. One class of mechanism involves nucleotide analogue discrimination either at the binding step or at the catalytic step, the latter being by far the most common mechanism. The other class of mechanism involves repair of the analogue-terminated DNA chain. The mechanisms were elucidated using purified reverse transcriptase and biochemical assays aimed at correlating resistant HIV-1 phenotypes to enzymatic data. The elucidation of these molecular mechanisms of drug-resistant reverse transcriptase is important for effective and rational combination therapies as well as for the conception of second-generation drugs that do not confer nucleotide resistance to reverse transcriptase or are active against pre-existing resistant viruses.
Collapse
Affiliation(s)
- Boulbaba Selmi
- Centre National de la Recherche Scientifique et Université d'Aix-Marseille I and II, UMR 6098, Architecture et Fonction des Macromolécules Biologiques, ESIL-Case 925, 163 avenue de Luminy, 13288 Marseille cedex 9, France
| | - Jérôme Deval
- Centre National de la Recherche Scientifique et Université d'Aix-Marseille I and II, UMR 6098, Architecture et Fonction des Macromolécules Biologiques, ESIL-Case 925, 163 avenue de Luminy, 13288 Marseille cedex 9, France
| | - Joëlle Boretto
- Centre National de la Recherche Scientifique et Université d'Aix-Marseille I and II, UMR 6098, Architecture et Fonction des Macromolécules Biologiques, ESIL-Case 925, 163 avenue de Luminy, 13288 Marseille cedex 9, France
| | - Bruno Canard
- Centre National de la Recherche Scientifique et Université d'Aix-Marseille I and II, UMR 6098, Architecture et Fonction des Macromolécules Biologiques, ESIL-Case 925, 163 avenue de Luminy, 13288 Marseille cedex 9, France
| |
Collapse
|
2
|
Fitzgibbon JE, DiCola MB, Arnold E, Das K, Sha BE, Pottage JC, Nahass R, Gaur S, John JF. HIV-1 Reverse Transcriptase Mutations Found in a Drug-Experienced Patient Confer Reduced Susceptibility to Multiple Nucleoside Reverse Transcriptase Inhibitors. Antivir Ther 2002. [DOI: 10.1177/135965350200600402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
HIV-1 reverse transcriptase (RT) genotypes were obtained from 13 patients treated with stavudine. No previously-reported mutations indicative of stavudine resistance were found in these patients and no novel mutations occurred in more than two patients. One patient, treated with stavudine for 1 month and treated previously with zidovudine, zalcitabine and lamivudine, carried a mutation at codon 75 of the RT (V75M). A chimeric virus, including the patient's RT sequence from codon 25 to codon 220, which carried the resistance mutations M41L, D67N, T69D, K70R, L210W and T215Y in addition to V75M, displayed reduced susceptibility to multiple nucleoside RT inhibitors (NRTIs). Removal of V75M from this RT background resulted in a return of susceptibility to didanosine and lamivudine. Our data are in agreement with previous studies demonstrating the rarity of stavudine resistance mutations in stavudine-treated patients. However, we describe a new set of mutations, found in the RT of a heavily-treated patient, that can confer reduced susceptibility to multiple NRTIs. These results underscore the importance of increased vigilance for possible multiple-drug resistance in patients who have been heavily treated with NRTIs.
Collapse
Affiliation(s)
- Joseph E Fitzgibbon
- Department of Medicine, Division of Allergy, Immunology and Infectious Diseases, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| | - May B DiCola
- Department of Medicine, Division of Allergy, Immunology and Infectious Diseases, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| | - Edward Arnold
- Center for Advanced Biotechnology and Medicine and Department of Chemistry, Rutgers University, Piscataway, NJ, USA
| | - Kalyan Das
- Center for Advanced Biotechnology and Medicine and Department of Chemistry, Rutgers University, Piscataway, NJ, USA
| | - Beverly E Sha
- Department of Medicine, Section of Infectious Diseases, Rush Medical College, Chicago, Ill., USA
| | - John C Pottage
- Department of Medicine, Section of Infectious Diseases, Rush Medical College, Chicago, Ill., USA
| | - Ronald Nahass
- Department of Medicine, Division of Allergy, Immunology and Infectious Diseases, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| | - Sunanda Gaur
- Department of Pediatrics, Division of Immunology, Allergy and Infectious Diseases, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| | - Joseph F John
- Department of Medicine, Division of Allergy, Immunology and Infectious Diseases, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| |
Collapse
|
3
|
Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci U S A 2001; 98:13907-12. [PMID: 11698656 PMCID: PMC61140 DOI: 10.1073/pnas.241300698] [Citation(s) in RCA: 102] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2001] [Indexed: 11/18/2022] Open
Abstract
Transmission of HIV-1 with reduced susceptibility to antiretroviral drugs raises public health concerns. Through surveillance of drug-resistant HIV-1 in 603 treatment-naive, recently diagnosed HIV-1-infected persons, we identified a distinct group of viruses that have mutations at codon 215 of the reverse transcriptase (RT) gene that are different from either the wild-type (WT) T or the zidovudine (AZT)-selected T215Y/F. These mutations included 215D/C/S and were found in 20 patients (3.3%). The 215D, 215C, and 215S mutations differ from 215Y by a 1-nt change compared with 2 nt for the WT T215 and likely represent revertants of 215Y. These viruses all were found to have WT susceptibility to AZT, and all replicated efficiently as WT HIV-1(T215). However, differences in fitness among HIV-1(215D), HIV-1(215C), and HIV-1(215S) were seen when RT backgrounds were changed, demonstrating a role of the RT background in the selection of these revertants. In vitro selection with AZT showed that HIV-1(215D) and HIV-1(215C) acquired 215Y more rapidly than did WT HIV-1(T215), likely reflecting the need for only 1-nt change to evolve to 215Y. Our study demonstrates that HIV-1 with unusual mutations at codon 215 replicate efficiently, have WT susceptibility, and are commonly found in treatment-naive persons. The increased ability for selecting resistance mutations defines this class of WT HIV-1 and highlights the higher potential of these viruses to compromise the efficacy of antiretroviral therapy.
Collapse
Affiliation(s)
- J G Garcia-Lerma
- HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
| | | | | | | | | |
Collapse
|
4
|
Vandamme AM, Houyez F, Bànhegyi D, Clotet B, De Schrijver G, De Smet KAL, Hall WW, Harrigan R, Hellmann N, Hertogs K, Holtzer C, Larder B, Pillay D, Race E, Schmit JC, Schuurman R, Shulse E, Sönnerborg A, Miller V. Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up. Antivir Ther 2001. [DOI: 10.1177/135965350100600103] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
HIV drug resistance is one of the major limitations in the successful treatment of HIV-infected patients using currently available antiretroviral combination therapies. When appropriate, drug susceptibility profiles should be taken into consideration in the choice of a specific combination therapy. Guidelines recommending resistance testing in certain circumstances have been issued. Many clinicians have access to resistance testing and will increasingly use these results in their treatment decisions. In this document, we comment on the different methods available, and the relevant issues relating to the clinical application of these tests. Specifically, the following recommendations can be made: (i) genotypic and phenotypic HIV-1 drug resistance analyses can yield complementary information for the clinician. However, insufficient information currently exists as to which approach is preferable in any particular clinical setting; (ii) when HIV-1 drug resistance testing is required, it is recommended that testing be performed on plasma samples obtained before starting, stopping or changing therapy, on samples that have a viral load above the detection limit of the resistance test; (iii) the panel recommends that genotypic and phenotypic HIV-1 drug resistance testing for clinical purposes be performed in a certified laboratory under strict quality control and quality assurance standards; and (iv) the panel recommends that resistance testing laboratories provide clinicians with resistance reports that include a list of drug-related resistance mutations (genotype) and/or a list of drug-related fold resistance values (phenotype), with interpretations of each by an experienced virologist. The interpretation of genotypic and phenotypic analysis is a complex and developing science, and in order to understand HIV-1 drug resistance reports, communication between the requesting clinician and the expert that interpreted the resistance report is recommended.
Collapse
Affiliation(s)
- A-M Vandamme
- AIDS Reference Laboratory, Rega Institute and University Hospitals, KU Leuven, Leuven, Belgium
| | | | | | - B Clotet
- Fundacio IRSI-Caixa, Badalona, Spain
| | | | | | - WW Hall
- Virus Reference Laboratory, University College, Dublin, Ireland
| | - R Harrigan
- BC Center for Excellence in HIV/AIDS, Vancouver, Canada (currently at Virco, UK)
| | | | - K Hertogs
- Virco, Mechelen, Belgium and Virco, UK
| | | | - B Larder
- Virco, Mechelen, Belgium and Virco, UK
| | - D Pillay
- PHLS Antiviral Susceptibility Reference Unit, University of Birmingham Medical School, UK
| | - E Race
- Hôpital Bichat-Claude Bernard, France (currently at VIRalliance, France)
| | - J-C Schmit
- Centre Hospitalier de Luxembourg, Luxembourg
| | - R Schuurman
- Eijkman-Winkler Institute, Utrecht University, Utrecht, The Netherlands
| | - E Shulse
- Applied Biosystems, Foster City, Calif., USA
| | | | - V Miller
- Klinikum der JW Goethe Universität, Frankfurt, Germany
| |
Collapse
|